A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

What Was Tested

This registered phase 4 trial tested Tirzepatide.

It had two arms (groups): Tirzepatide (experimental) and one (active comparator).

Participants will receive an antihyperglycemic medication.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 780 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have, within the last 4 years, been diagnosed with T2D based on the World Health Organization classification or other locally applicable diagnostic standards. Have been on a stable treatment of metformin only at least 90 days preceding baseline.

The full record lists 5 inclusion and 18 exclusion criteria; among the exclusions: have type 1 diabetes mellitus; have a history of chronic or acute pancreatitis any time prior to study entry; have a history of.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Tirzepatide group and the comparison group ran side by side rather than switching.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2022-08-01 with completion listed for 2025-10-21.

It ran at 90 sites in United States (32), Israel (9), Germany (8), Italy (8), Romania (7) and United Kingdom (7).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change from Baseline in Hemoglobin A1c (HbA1c) (time frame: Baseline, Week 104).

It also tracked 33 secondary outcomes, for example Change from Baseline in HbA1c, Change from Baseline in Weight, Change from Baseline in Weight, Change from Baseline in Waist Circumference, Change from Baseline in Waist Circumference and Change from Baseline in Fasting Serum Glucose (FSG).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Tirzepatide in 780 people.

With 780 participants it is a large trial for this field.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.